Regulatory7 min read
Empower Pharmacy FDA Letter: The B12 Loophole Just Closed
The FDA told Empower Pharmacy its B12 and niacinamide GLP-1 add-ins are 'essentially copies.' What the letter says and where compounded supply goes now.
Peptide News & Analysis
FDA actions, trial readouts, vendor coverage and pricing reports — curated for peptide buyers and clinicians.
Daily Peptide News
New articles delivered to your inbox every morning. Free.
Latest News
Industry7 min read
Peptides for Dogs: Wolverine Stack Trend Goes Mainstream
Dog owners report giving pets BPC-157 and TB-500 — the Wolverine stack. What Business Insider found, what vets say, and what animal research shows.
Trials7 min read
Brenipatide: Lilly's Next GIP/GLP-1 Targets the Brain
Lilly's brenipatide enters Phase 3 for alcohol use disorder and depression — a weekly GIP/GLP-1 built for the brain. What GLP-1 buyers should watch.
Trials5 min read
Roche's Enicepatide: 15.5% Weight Loss in Diabetes Trial
Roche's dual GLP-1/GIP shot cut weight 15.5% and HbA1c 2.65 points in type 2 diabetes — 62% hit non-diabetic blood sugar. What it means for buyers.
Industry6 min read
VK2735 Maintenance Data: Monthly Dosing Holds Up to 90%
Viking's VK2735 held up to 97% of weight loss on biweekly dosing and 90% monthly. What the first GLP-1 maintenance data means for peptide buyers.
Industry11 min read
CagriSema Beats Tirzepatide 5 mg in REIMAGINE 5
Novo reported CagriSema hit 12.4% weight loss vs 9.1% for tirzepatide 5 mg — and 21% at 42% of the full dose. What the low-dose data means for buyers.
Industry9 min read
Wall Street Puts the Peptide Market at $80 Billion
A Citigroup survey says 28% of respondents used a peptide at $90 a month, scaling to $80B a year. What that number counts — and what it leaves out.
Vendors2 min read
Is Royal Peptides Legit? COAs, Prices & Verdict
Royal Peptides: multi-region fulfillment and third-party COAs — real pricing and our honest verdict, plus the better-vetted vendors we track.
Vendors1 min read
Is Puratek Peptides Legit? COAs, Prices & Verdict
Puratek Peptides: healing compounds, GLP analogs, and blends — COA testing, real pricing, and our honest verdict on whether it's worth it.
Vendors3 min read
Is Penguin Peptides Legit? COAs, Prices & Verdict
Penguin Peptides: batch COA testing, real pricing, and our honest verdict — plus the better-vetted vendors we'd buy from instead.
Industry11 min read
Montana's Unapproved-Drug Clinics: Do Peptides Qualify?
Montana now licenses clinics to sell drugs that cleared only Phase 1. We ran the registry on the six peptides the FDA panel backed. None clears the bar.
Vendors1 min read
Is Crush Research Legit? GLP-1 Prices & COAs
Crush Research, the veteran-owned GLP-1 vendor: COA testing, real pricing, and where to source the same compounds cheaper. Honest verdict inside.
Vendors3 min read
Is AminoClub Legit? COA, Testing & Verdict
AminoClub claims ISO-lab testing and 99%+ purity, but its COAs hide behind an app. We checked the testing, reputation, and our honest verdict.
Industry9 min read
BPC-157 Use Up 33x: First Real-World Patient Data
A data firm screened 15 million medical records and found 1,039 documented BPC-157 users. Use rose 33-fold since 2020 — and the typical user changed.
Industry9 min read
Peptide COA: Why 99% Purity Isn't Enough
A 99% pure peptide can still be risky — the other 1% is the question. What identity and related-substances testing reveal that a purity figure hides.
Industry8 min read
BPC-157 Human Trial: US University Tests Rotator Cuff
A US university registered a randomized, placebo-controlled BPC-157 trial in shoulder surgery — 90 days of daily injections. What the protocol tests.
Trials8 min read
EloraTZP: Eloralintide + Tirzepatide Hits 17% Loss
Lilly's eloraTZP — eloralintide plus tirzepatide — hit 17% weight loss in 16 weeks vs 10% on tirzepatide alone. Phase 2 data lands at EASD Sept 30.
Industry9 min read
UCLA Reviewed 565 Peptide Studies: What It Found
UCLA orthopedists screened 565 studies on BPC-157, TB-500, GHK-Cu and three more. What the scoping review found — and the limit on its scope.